Prescription Drug Pricing and Medicaid Fraud Prevention Act of 2005 - Amends title XIX (Medicaid) of the Social Security Act to require the Secretary of Health and Human Services to disclose publicly the average manufacturer prices (AMP) and best prices for prescription drugs.
Requires each drug manufacturer with a rebate agreement in effect to report to the Secretary detailed information (specified by the Secretary) on how the AMP is computed, including assumptions used.
[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3546 Introduced in House (IH)]
109th CONGRESS
1st Session
H. R. 3546
To amend title XIX of the Social Security Act to provide for public
disclosure of average manufacturer prices (AMP) and best prices for
prescription drugs.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
July 28, 2005
Mr. Emanuel (for himself, Mr. Case, Mr. Lipinski, Ms. Herseth, and Mr.
Doggett) introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend title XIX of the Social Security Act to provide for public
disclosure of average manufacturer prices (AMP) and best prices for
prescription drugs.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Prescription Drug Pricing and
Medicaid Fraud Prevention Act of 2005''.
SEC. 2. PUBLIC DISCLOSURE OF AVERAGE MANUFACTURER PRICES (AMP) AND BEST
PRICES FOR PRESCRIPTION DRUGS.
(a) Public Disclosure.--Subparagraph (D) of section 1927(b)(3) of
the Social Security Act (42 U.S.C. 1396r-8(b)(3)) is amended--
(1) by striking ``and'' at the end of clause (ii);
(2) by striking the period at the end of clause (iii) and
inserting ``, and''; and
(3) by inserting after clause (iii) the following new
clause:
``(iv) that the Secretary shall make
publicly available the information reported
under subparagraph (A)(i) on average
manufacturer price and best price for each
covered outpatient drug.''.
(b) Reporting of Methodology and Assumptions for Computing Average
Manufacturer Price.--Subparagraph (A) of such section is amended by
adding at the end the following: ``The information reported under
clause (i) shall include detailed information (specified by the
Secretary) on how the manufacturer computes the average manufacturer
price, including assumptions used in computing such price.''.
(c) Effective Date.--The amendments made by this section shall
apply to rebate agreements, and information reported under such
agreements, as of the date that is first day of the first calendar
quarter beginning after the date of the enactment of this Act.
<all>
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line